MedTrace Logo

Treatment of Oral Warts in HIV+ Patients

NCT00454181 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 59

Last updated 2011-09-16

Study results available
· View outcomes & findings →

Summary

This is a study to test lozenges of interferon-alpha that are dissolved in the mouth as a treatment of oral warts in HIV-positive adults.

The hypothesis of this study is that interferon-alpha will be safe and that a higher percentage of subjects given interferon-alpha will experience a complete or nearly complete remission of their oral warts compared to subjects given placebo.

Conditions

  • Papillomatosis
  • HIV Infections

Interventions

DRUG

Interferon-alpha

500 IU interferon-alpha lozenges taken 3 times per day for 24 weeks

OTHER

placebo

200 mg lozenges containing anhydrous crystalline maltose taken three times per day for 24 weeks

Sponsors & Collaborators

  • Ainos, Inc. (f/k/a Amarillo Biosciences Inc.

    lead INDUSTRY

Principal Investigators

  • Deborah Greenspan, BDS, DSc · University of California, San Francisco

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-02-28
Primary Completion
2009-09-30
Completion
2009-10-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00454181 on ClinicalTrials.gov